These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12385428)

  • 1. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials.
    Rutgeerts P
    Am J Gastroenterol; 2002 Oct; 97(10):2488-9. PubMed ID: 12385428
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inflammatory bowel disease: anti-TNF strategies and beyond].
    Hoffmann JC
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S76-8. PubMed ID: 15368175
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathways in the management of IBD. Foreword.
    Maconi G
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S213. PubMed ID: 18598990
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anti tumor necrosis factor alpha antibody: infliximab].
    Arimitsu S; Ito H
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():329-32. PubMed ID: 23126112
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.
    Rossetti S; Actis GC; Fadda M; Rizzetto M; Palmo A
    Dig Liver Dis; 2004 Jun; 36(6):426-31. PubMed ID: 15248385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
    Gonzalez-Lama Y; Fernandez-Blanco I; Lopez-SanRoman A; Taxonera C; Casis B; Tabernero S; Bermejo F; Martinez-Silva F; Mendoza JL; Martinez-Montiel P; Carneros JA; Sanchez F; Maté J; Gisbert JP;
    Hepatogastroenterology; 2008; 55(86-87):1609-14. PubMed ID: 19102352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab therapy for ulcerative colitis: many unanswered questions.
    Present DH
    Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CED therapy with infliximab. Rapid and lasting remission - complete mucosal healing].
    Wedekind S
    MMW Fortschr Med; 2011 Dec; 153(48):54-5. PubMed ID: 22299262
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of TNFalpha in ulcerative colitis.
    Sands BE; Kaplan GG
    J Clin Pharmacol; 2007 Aug; 47(8):930-41. PubMed ID: 17567930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Moss AC; Farrell RJ
    Gastroenterology; 2006 Nov; 131(5):1649-51; discussion 1651. PubMed ID: 17067595
    [No Abstract]   [Full Text] [Related]  

  • 18. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM; Schmidt D; Karlén P
    Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab for ulcerative colitis.
    Shields CJ; Winter DC
    N Engl J Med; 2006 Mar; 354(13):1424-6; author reply 1424-6. PubMed ID: 16571891
    [No Abstract]   [Full Text] [Related]  

  • 20. Does it all ADA up? Adalimumab for ulcerative colitis.
    Travis S
    Gut; 2011 Jun; 60(6):741-2. PubMed ID: 21257988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.